[adinserter block="3"]
[adinserter block="3"]
No Picture
News

UTMB and HDT Bio awarded prototype project funding worth up to $87.4M from the U.S. government to develop saRNA vaccine technology

GALVESTON, Texas & SEATTLE–(BUSINESS WIRE)–Two deadly viruses significant to the military to be targets for vaccine protection: Crimean-Congo hemorrhagic fever virus and Nipah virus. Click here to view original post

[adinserter block="3"]
No Picture
News

Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors

─First-in-Human Phase 1 Clinical Trial in Advanced Solid Tumors is Being Conducted by MD Anderson with an Investment from Cancer Focus Fund ─ ─Extension Brings in New Investor Israel Biotech Fund (IBF), with Additional Participation […]